A Study of TCD601 in de Novo Renal Transplant Recipients
Public ClinicalTrials.gov record NCT05669001. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination With Belatacept and MPA Compared to Standard of Care Immunosuppression in de Novo Renal Transplant Recipients (ASCEND)
Study identification
- NCT ID
- NCT05669001
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- ITB-Med LLC
- Industry
- Enrollment
- 76 participants
Conditions and interventions
Conditions
Interventions
- ATG Drug
- Corticosteroids Drug
- MPA Drug
- TAC Drug
- TCD601 Biological
- belatacept Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 27, 2023
- Primary completion
- Apr 9, 2026
- Completion
- Apr 9, 2026
- Last update posted
- May 4, 2026
2023 – 2026
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Davis Medical Center | Sacramento | California | 95817 | — |
| University of California San Francisco Medical Center | San Francisco | California | 94143 | — |
| Tampa General Hospital | Tampa | Florida | 33606 | — |
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Atrium Health Wake Forest Baptist Medical Center | Winston-Salem | North Carolina | 27157 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Houston Methodist Hospital | Houston | Texas | 77030 | — |
| University of Virginia Health | Charlottesville | Virginia | 22903 | — |
| Inova Fairfax Hospital Medical Campus | Falls Church | Virginia | 22042 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05669001, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05669001 live on ClinicalTrials.gov.